383 completed, 71 unknown, 56 terminated, 54 recruiting. 645 Phase 2, 107 Phase 1, 55 Phase 3.
Follow Parkinsonian Disorders: new trials by email Literature Review of Parkinsonian Disorders trials Research Report on Parkinsonian Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Terazosin And Metabolic Energetics in Parkinson's Disease Terazosin 5 MG, Placebo - Parkinson's Disease (PD) | Phase 2 | Suspended | Ergun Y. Uc | 120 | 2028-07-01 | 2026-10-09 |
| Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients. Gemfibrozil, Placebo - Parkinson Disease | Phase 2 | Withdrawn | Forest Hills Lab | 2027-11-01 | 2026-08-19 | |
| Terazosin for Dementia With Lewy Bodies Terazosin Hydrochloride, Placebo - Dementia With Lewy Bodies | Phase 1 / Phase 2 | Not yet recruiting | Qiang Zhang | 40 | 2027-10-01 | 2026-03-12 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease MT101-5 - Parkinson's Disease | Phase 2 | Not yet recruiting | Mthera Pharma Co., Ltd. | 120 | 2027-09-01 | 2026-10-16 |
| Sustained Release Oral Formulation For Treatment Of Parkinsons Disease Formulation A, Formulation B, Formulation C - Healthy Volunteers | Phase 1 / Phase 2 | Not yet recruiting | University of Minnesota | 32 | 2027-04-01 | 2026-10-01 |
| A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD) AB-1005 - Parkinson Disease | Phase 2 | Not yet recruiting | Bayer | 8 | 2027-01-25 | 2026-07-29 |
| Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease Talineuren, Placebo - Parkinson Disease | Phase 2 | Not yet recruiting | InnoMedica Schweiz AG | 40 | 2027-01-01 | 2026-10-30 |
| Gene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical Study Injecting KL002 into the bilateral putamen - Parkinson's Disease (PD), Advanced Primary PD | Phase 1 / Phase 2 | Not yet recruiting | Kanglin Biotechnology (Hangzhou) Co., Ltd. | 12 | 2027-01-01 | 2026-11-16 |
| Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease Sitagliptin, Sitagliptin placebo - Parkinson Disease | Phase 2 | Not yet recruiting | Yonsei University | 160 | 2026-12-15 | 2026-09-10 |
| A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease 60 milligrams of ENERGI-F705 Tablets, Placebo tablets, 120 milligrams of ENERGI-F705 Tablets - Parkinson's Disease (PD) | Phase 2 | Not yet recruiting | Energenesis Biomedical Co., Ltd. | 105 | 2026-12-01 | 2026-07-02 |
| A Phase 1/2a Clinical Study of KL002 in Treatment of Parkinson's Disease Injecting KL002 into the bilateral putamen - Parkinson's Disease (PD), PD | Phase 1 / Phase 2 | Not yet recruiting | Kanglin Biotechnology (Hangzhou) Co., Ltd. | 12 | 2026-12-01 | 2026-11-10 |
| Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism Intrathecal (IT), Intravenous - Parkinsonism or Parkinson's Disease Nos, Parkinsonism in Diseases Classified Elsewhere | Phase 2 | Not yet recruiting | Biocells Medical | 120 | 2026-11-23 | 2026-03-13 |
| Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease RO7568282, Placebo - Parkinson's Disease | Phase 2 | Recruiting | Hoffmann-La Roche | 474 | 2026-11-11 | 2026-11-16 |
| Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA) Prescriptive Infusion Algorithm, AB-1005 - PARKINSON DISEASE (Disorder) | Phase 2 | Not yet recruiting | AskBio Inc | 18 | 2026-11-01 | 2026-10-29 |
| Lemborexant on Perioperative Sleep Quality in Patients With Parkinson's Disease Undergoing Deep Brain Stimulation Lemborexant 5 mg, Placabo - Parkinson Disease (PD), Sleep Initiation and Maintenance Disorders | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 128 | 2026-11-01 | 2026-10-29 |
| Prevent Cognitive Decline in GBA-associated Parkinson's Disease Prasinezumab, Sodium Chloride - Parkinson's Disease | Phase 2 | Recruiting | University Hospital Tuebingen | 120 | 2026-10-01 | 2026-10-23 |
| Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy | Phase 1 / Phase 2 | Recruiting | Prabesh Kanel | 15 | 2026-10-01 | 2026-11-05 |
| DaxibotulinumtoxinA for Blepharospasm Botulinum Neurotoxin Type A - Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid | Phase 2 | Recruiting | University of Pennsylvania | 20 | 2026-09-24 | 2026-09-29 |
| Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease UX-DA003 - Parkinson's Disease | Phase 1 / Phase 2 | Recruiting | Shanghai UniXell Biotechnology Co., Ltd | 12 | 2026-09-24 | 2026-11-04 |
| RESvEraTrol in Parkinson's Disease (RESET) Trans-Resveratrol - Parkinson's Disease | Phase 2 | Recruiting | Georgetown University | 30 | 2026-09-17 | 2026-09-18 |
Showing 20 of 645. Sign in to see all of them.
Parkinson Disease (603) · Dyskinesias (44) · Lewy Body Disease (37) · Movement Disorders (33) · Neurodegenerative Diseases (23) · Dementia (17) · Cognitive Dysfunction (15) · Alzheimer Disease (14) · Brain Diseases (13) · Central Nervous System Diseases (12) · Depression (12) · REM Sleep Behavior Disorder (12) · Tremor (10) · Dyskinesia, Drug-Induced (9)
Basal Ganglia Diseases (639) · Nervous System Diseases (636) · Central Nervous System Diseases (633) · Brain Diseases (632) · Synucleinopathies (630) · Neurodegenerative Diseases (613) · Movement Disorders (612) · Pathological Conditions, Signs and Symptoms (106) · Mental Disorders (94) · Signs and Symptoms (86) · Neurologic Manifestations (71) · Neurocognitive Disorders (55) · Dementia (33) · Pathologic Processes (23)
Levodopa (31) · carbidopa, levodopa drug combination (23) · Carbidopa (12) · Apomorphine (10) · Donepezil (8) · istradefylline (8) · mavoglurant (8) · Sodium Chloride (7) · entacapone (7) · Pramipexole (6) · perampanel (6) · rotigotine (6) · Ambroxol (5) · Droxidopa (5) · Saline Solution (5)
National Institute of Neurological Disorders and Stroke (NINDS) (21) · Institute for Neurodegenerative Disorders (11) · Chang Gung Memorial Hospital (8) · Eisai Inc. (8) · Axovant Sciences Ltd. (7) · Biogen (6) · Kyowa Kirin Co., Ltd. (6) · Novartis (6) · Tanta University (6) · University College, London (6) · University Hospital, Toulouse (6) · Georgetown University (5) · Impax Laboratories, LLC (5) · Integrative Research Laboratories AB (5) · Novartis Pharmaceuticals (5)
United States (318) · France (70) · United Kingdom (53) · Germany (52) · Canada (49) · Italy (40) · Spain (39) · China (29) · Japan (28) · Israel (25) · Poland (23) · Netherlands (21) · Austria (19) · Sweden (16) · Taiwan (16)
Danna Jennings, MD (6) · Ilise Lombardo, MD (6) · Fernando L Pagan, MD (4) · Kyoji Imaoka, Mr (4) · John G. Nutt, MD (3) · Neil Sussman, MD (3) · Abraham Lieberman, MD (2)
PMID 36602886, PMID 38588457, PMID 40680102, PMID 31356217, PMID 17941858, PMID 21484867, PMID 24412048, PMID 24711047, PMID 27214258, PMID 36849448, PMID 38072889, PMID 38706271, PMID 10214756, PMID 10406987, PMID 10527042, PMID 10853813, PMID 10979878, PMID 11076832, PMID 11400186, PMID 11724917, PMID 12222941, PMID 12465055, PMID 12498954, PMID 12771261, PMID 12904089, PMID 1454205, PMID 15175402, PMID 15331239, PMID 15345186, PMID 15590952, PMID 15645531, PMID 15779234, PMID 15956161, PMID 16025231, PMID 16214880, PMID 16376913, PMID 16442563, PMID 16715205, PMID 16837857, PMID 17190953, PMID 17353373, PMID 17881719, PMID 17940108, PMID 18079166, PMID 18268187, PMID 18349024, PMID 18413464, PMID 18442107, PMID 18474731, PMID 18519872
2016 (6), 2023 (6), 2008 (4), 2015 (4), 2017 (4), 2009 (3), 2025 (3), 2018 (2), 2019 (2), R01NS021062 (2), R01NS099535 (2), U01NS043128 (2), 1UG3NS133515-01A1 (1), 2004 (1), 2005 (1)